Iovance Biotherapeutics raised FY2026 revenue guidance to $410M-$420M on strong demand for Amtagvi and Proleukin. The new midpoint is $55M above prior outlook and implies about 60% annual revenue growth.
published
Iovance Biotherapeutics raised FY2026 revenue guidance to $410M-$420M on strong demand for Amtagvi and Proleukin. The new midpoint is $55M above prior outlook and implies about 60% annual revenue growth.
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.